SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-20-083232
Filing Date
2020-03-24
Accepted
2020-03-24 08:33:02
Documents
6
Effectiveness Date
2020-03-24

Document Format Files

Seq Description Document Type Size
1 DEFA14A d883309ddefa14a.htm DEFA14A 45262
2 GRAPHIC g883309page10a.jpg GRAPHIC 1500
3 GRAPHIC g883309page10b.jpg GRAPHIC 2393
4 GRAPHIC g883309page11a.jpg GRAPHIC 1507
5 GRAPHIC g883309page12a.jpg GRAPHIC 1499
6 GRAPHIC g883309page9a.jpg GRAPHIC 1483
  Complete submission text file 0001193125-20-083232.txt   58773
Mailing Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102
Business Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102 206-732-2133
Neoleukin Therapeutics, Inc. (Filer) CIK: 0001404644 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36327 | Film No.: 20736685
SIC: 2834 Pharmaceutical Preparations